Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | May 24, 2024
Product Development
Clinical Report: Merus data stand out among ASCO highlights
Clinical data released ahead of ASCO from Merus, Caribou, BioNTech and more
BioCentury | Mar 8, 2024
Product Development
Pfizer blends modality tools in new vision for oncology unit
Pharma outlines goals for oncology business as it moves to integrate ADC play Seagen
BioCentury | Jul 5, 2023
Deals
July 5 Quick Takes: Moderna to invest in products for China market
Plus: China-based Worg raises $152M series C and updates from Innovent, IASO, Jacobio, FDA, Amneal, Sarepta and more
BioCentury | Apr 25, 2023
Data Byte
Aggressive cuts part of Novartis’ focus on higher-potential pipeline
The pharma’s latest quarterly update revealed a pruning of 10% of its pipeline, including several early-stage cancer programs
BioCentury | Sep 8, 2022
Product Development
Relay racing down accelerated pathway with promising bile duct cancer readout
Latest data cut shows response rates to computationally designed selective FGFR2 inhibitor, built for efficacy with improved safety profile
BioCentury | Aug 8, 2022
Product Development
Amgen’s combination strategy for Lumakras takes a blow with disappointing checkpoint inhibitor data
Added toxicity derails a key combination for Amgen’s KRAS inhibitor
BioCentury | May 12, 2022
Deals
BMS gains license to BridgeBio’s SHP-2, already in deal for Opdivo combo
Pharma pays $90M up front for rights to small molecule that could become a once-daily option in combinations for some cancers
BioCentury | Oct 9, 2021
Discovery & Translation
Improved guide RNAs for prime editing; plus J&J, Synlogic and more
BioCentury’s roundup of translational news
BioCentury | Sep 19, 2021
Product Development
Mirati data underscore KRAS opportunity in colorectal cancer
Mirati’s latest KRAS inhibitor data point to a potential efficacy advantage in colorectal cancer
BioCentury | May 26, 2021
Finance
Building on discovery platform and early deals, CBC-backed NiKang adds $200M in crossover series C round
With backing from high-profile crossover investors, four-year-old company taking wholly-owned HIF2A program into clinic
Items per page:
1 - 10 of 64